Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHalma Regulatory News (HLMA)

Share Price Information for Halma (HLMA)

Share Price is delayed by 15 minutes
Get Live Data
4,664.00    -214.00 (-4.39%)
Bid:
4,682.00
Ask:
4,686.00
Spread: 4.00 (0.085%)
Market Cap: £17.62b
HLMA Live PriceLast checked at - London Stock Exchange

Intraday Halma Share Chart

Trading Statement

27 Sep 2017 07:00

RNS Number : 8921R
Halma PLC
27 September 2017
 

Halma plc

 

Trading Update

 

27 September 2017

 

Trading Update

 

Halma, the leading safety, health and environmental technology group today releases its scheduled Trading Update, relating to trading for the period from 2 April 2017.

 

Halma made good progress in line with the Board's expectations. The improved rates of organic constant currency revenue and profit growth achieved in the second half of the last financial year have continued into the current year. Order intake was ahead of revenue and also ahead of the same period last year.

 

There was widespread growth geographically, with organic constant currency revenue increases in all major regions. Asia Pacific maintained strong growth, with good progress in the UK and Mainland Europe and a steady performance in the USA.

 

The Environmental & Analysis sector performed particularly well, benefitting from strong growth in Asia Pacific and the re-organisation in its Life Science and Research business during the first half of last year.

 

The improved performance achieved by the Process Safety sector in the second half of last year continued. Market diversification and rising demand from the US onshore energy market both contributed to significant growth over the prior year.

 

The Infrastructure Safety sector continued to achieve good growth as greater investment in new product development in recent years contributed towards increasing demand from Asia Pacific and Mainland Europe.

 

The Medical sector also achieved solid revenue growth, although profitability was lower due to increased investment in new product development and sales resources.

 

In August 2017, we announced the acquisitions of Cardios for an initial consideration of R$50m (£12.1m) and CASMED for $4.5m (£3.4m). Both businesses strengthen our Medical sector's blood pressure monitoring technology base, with Cardios also being Halma's first acquisition in Brazil. The integration of both businesses is progressing well.

 

Our M&A pipeline strengthened during the period. We continue to search for businesses in, or adjacent to, all four sectors and the additional sector resources added during 2016 have improved both the quantity and quality of our opportunities.

 

Cash generation was good and the Group's financial position remains strong.

 

The results for the half year ending 30 September 2017 will be released on 21 November 2017.

 

 

 

 

For further information, please contact:

 

Halma plc Tel: +44 (0)1494 721111

Andrew Williams, Chief Executive

Kevin Thompson, Finance Director

 

MHP Communications Tel: +44 (0)20 3128 8100

Rachel Hirst/Andrew Jaques

 

 

Notes:

 

1.

This Trading Update is based on unaudited management accounts information and has been prepared solely to provide additional information to the shareholders of Halma plc. It should not be relied on by any other party, for other purposes. Forward-looking statements have been made by the Directors in good faith using information available up until the date that they approved this statement. Forward-looking statements should be regarded with caution because of the inherent uncertainties in economic trends and business risks.

 

2.

A copy of this announcement, together with other information about Halma, may be viewed on its website: www.halma.com

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBLGDCUDDBGRL
Date   Source Headline
15th Oct 20211:06 pmRNSDirector/PDMR Shareholding
4th Oct 20212:12 pmRNSDirector/PDMR Shareholding
23rd Sep 20211:01 pmRNSDirector/PDMR Shareholding
22nd Sep 20217:00 amRNSTrading update
9th Sep 202110:22 amRNSDirector Declaration
9th Aug 20217:00 amRNSM&A Update
26th Jul 202111:01 amRNSDirector/PDMR Shareholding
22nd Jul 20213:00 pmRNSResult of AGM
5th Jul 20214:05 pmRNSDirector/PDMR Shareholding
30th Jun 20211:50 pmRNSDirector/PDMR Shareholding
23rd Jun 20214:47 pmRNSAnnual Financial Report
10th Jun 20217:01 amRNSUnaudited restated segmental information
10th Jun 20217:00 amRNSFull Year Results 2021
27th Apr 20217:00 amRNSAcquisition
26th Mar 20217:00 amRNSAppointment of independent non-executive Director
24th Mar 20217:00 amRNSTrading update
23rd Feb 20217:54 amRNSDirector Declaration
10th Feb 20214:52 pmRNSDirector/PDMR Shareholding
9th Feb 20217:00 amRNSDirectorate Change
21st Dec 20202:00 pmRNSAcquisition
18th Dec 20207:00 amRNSDisposal
4th Dec 20207:04 amRNSDirector Declaration
2nd Dec 20204:08 pmRNSDirector/PDMR Shareholding
25th Nov 20203:20 pmRNSDirector/PDMR Shareholding
19th Nov 20207:00 amRNSHALF YEAR RESULTS 2020/21
5th Oct 20201:12 pmRNSDirector/PDMR Shareholding
23rd Sep 20207:05 amRNSDirector Declaration
23rd Sep 20207:00 amRNSChair retirement
23rd Sep 20207:00 amRNSTrading update
4th Sep 20204:57 pmRNSResult of AGM
31st Jul 20204:06 pmRNSDirector/PDMR Shareholding
24th Jul 20205:02 pmRNSAnnual Financial Report
17th Jul 20209:32 amRNSDirector/PDMR Shareholding
14th Jul 20207:00 amRNSFinal Results
15th May 20201:29 pmRNSElectronic Communications with Shareholders
27th Apr 202012:46 pmRNSDisclosure of Rights Attached to Equity Shares
21st Apr 20207:00 amRNSCOVID-19 Update
2nd Apr 20207:05 amRNSExecutive Board changes
19th Mar 20207:00 amRNSTrading Statement
5th Mar 20209:00 amRNSInvestor Event
24th Feb 202011:31 amRNSHolding(s) in Company
21st Feb 20207:00 amRNSAcquisition
5th Feb 20207:00 amRNSAcquisition
27th Jan 20207:00 amRNSAcquisition
22nd Jan 202012:58 pmRNSChange of Remuneration Committee Chair
29th Nov 20191:27 pmRNSDirector/PDMR Shareholding
25th Nov 20195:10 pmRNSDirector/PDMR Shareholding
19th Nov 201911:45 amRNSDividend Declaration
19th Nov 20197:00 amRNSHalf-year Report
2nd Oct 20195:02 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.